Latest News and Press Releases

Findings show roluperidone increases release and gene expression of BDNF, as well as release of GDNF Data presented at 2019 Congress of the Schizophrenia International Research Society WALTHAM,...

WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

WALTHAM, Mass., May 03, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

WALTHAM, Mass., March 05, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Multi-center, international trial targets significant unmet need for which no treatments are approved Approximately 500 patients to be enrolled at 60 clinical sites in U.S. and Europe WALTHAM,...

FDA feedback on clinical trial design and completion of bridging study with new formulation enable initiation of Phase 3 trial with MIN-101 to treat negative symptoms of schizophrenia in second half...

WALTHAM, Mass., July 31, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Pivotal Phase 3 trial design to include monotherapy administration of MIN-101 and primary endpoint of improvement in negative symptoms of schizophrenia Planned initiation of MIN-101 Phase 3...

WALTHAM, Mass., May 04, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central...

Multiple positive data readouts during 2016 provide foundation for initiation of advanced clinical trials with three product candidates in 2017   Management to host conference call today at...